introduction phosphodiesterase type 5 pde5 inhibitors are the first line drugs for treatment of erectile dysfunctionsildenafil viagrar tadalafil cialisr and vardenafil levitrar are from the same class of drugs that inhibit pde5transient visual symptoms such as change in color perception and increased light sensitivity are wellknown adverse effects of these drugs and occur in 311 of sildenafil usersvisionthreatening serious ocular complications such as nonarteritic ischemic optic neuropathy and cilioretinal artery occlusion have rarely been reported in pde5 inhibitor usersaims to highlight and analyze the most recently published case literature on serious ocular complications of pde5 inhibitorsmethods search of the peerreviewed english literature was conducted using medlinethe following databases also were searched cumulative index to nursing and allied health literature cochrane library global health and md consultthe causality assessment of the reported adverse drug reactions was analyzed by applying both the world health organization who probability scale and the criteria utilized by the national registry of druginduced ocular side effectsmain outcome measures to scientifically and objectively find out if pde5 inhibitors are associated with visionthreatening ocular complicationsresults eight case reports of serious pde5 inhibitorassociated ocular complications were identified since january 2006 until february 2011case reports included cases of anterior and posterior nonarteritic ischemic optic neuropathy central retinal vein occlusion cilioretinal artery occlusion acute angle closure glaucoma and optic atrophy after sildenafil useconclusion there is lack of conclusive evidence to indicate a direct causeeffect relationship between pde5 inhibitor use and visionthreatening ocular eventsmen who use pde5 inhibitors appear to suffer visionthreatening complications at the same frequency as the general populationhowever minor visual adverse effects occur in 311 of users and they are transient and reversible 2011 international society for sexual medicine